Department of Justice Issues Positive Business Review Letter to Companies Developing Plasma Therapies for Covid-19
The convalescent plasma can be given to patients directly, through infusion, or used to make hyperimmune globulin (HIg) therapies. This is the sixth expedited COVID-19 business review letter issued by the department since the department and the Federal Trade Commission first set out an expedited, temporary review procedure in the Joint Antitrust Statement Regarding COVID-19 (the “Joint Statement”). In April 2020, the department issued expedited business review letters to certain distributors of personal protective equipment (PPE) as well as the pharmaceuticals distributor AmerisourceBergen. After a 30-day waiting period, any documents supporting the business review will be added to the file, unless a basis for their exclusion for reasons of confidentiality has been established under the business review procedure. Supporting documents in the file will be maintained for a period of one year, and copies will be available upon request to the FOIA/Privacy Act Unit, Antitrust Documents Group at atrdocs.grp@usdoj.gov.
justice.gov